Adjuvant erlotinib (E) versus placebo (P) in non-small cell lung cancer (NSCLC) patients (pts) with tumors carrying EGFR-sensitizing mutations from the RADIANT trial.

• DOI: 10.1200/jco.2014.32.15_suppl.7513
• Publication Date: 2019-01-03T22:35:36Z
• Authors: Frances A. Shepherd; Nasser K. Altorki; Wilfried Ernst Er...; Mary E.R. O'Brien; David R. Spigel; Lucio Crino; Chun-Ming Tsai; Joo-Hang Kim; Eun Kyung Cho; Aleksandra Szczesna; Otto Burghuber; Philip C. Hoffman; Shaf Keshavjee; Sergey Orlov; Piotr Serwatowski; Jiuzhou Wang; Margaret A. Foley; Julie D. Horan; Frank C Richardson; Karen Kelly
• Keywords: 03 medical and health sciences; 0302 clinical medicine; Medizin; 3. Good health

7513 Background: E, anEGFR TKI, prolongs survival in pts with advanced NSCLC. Pts with tumors carrying EGFR exon 19 del or 21 L858R mutations are particularly sensitive to EGFR TKIs. Methods: RADIA...